Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management Makes New Investment in SPDR S&P Biotech ETF $XBI

Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management purchased a new position in SPDR S&P Biotech ETF (NYSEARCA:XBI) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 65,000 shares of the exchange traded fund’s stock, valued at approximately $7,925,000. SPDR S&P Biotech ETF comprises about 1.1% of Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management’s holdings, making the stock its 20th largest holding. Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management owned approximately 0.10% of SPDR S&P Biotech ETF as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in XBI. JPMorgan Chase & Co. lifted its position in shares of SPDR S&P Biotech ETF by 27.3% in the third quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock worth $1,356,582,000 after buying an additional 2,900,633 shares during the last quarter. Assetmark Inc. lifted its position in shares of SPDR S&P Biotech ETF by 1,042,265.6% in the fourth quarter. Assetmark Inc. now owns 635,843 shares of the exchange traded fund’s stock worth $77,528,000 after buying an additional 635,782 shares during the last quarter. Greenwoods Asset Management Hong Kong Ltd. acquired a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter worth about $55,613,000. Ameriprise Financial Inc. lifted its position in shares of SPDR S&P Biotech ETF by 123.0% during the 2nd quarter. Ameriprise Financial Inc. now owns 872,796 shares of the exchange traded fund’s stock worth $72,542,000 after purchasing an additional 481,408 shares during the last quarter. Finally, Meitav Investment House Ltd. lifted its position in shares of SPDR S&P Biotech ETF by 70.3% during the 3rd quarter. Meitav Investment House Ltd. now owns 682,056 shares of the exchange traded fund’s stock worth $68,156,000 after purchasing an additional 281,602 shares during the last quarter.

SPDR S&P Biotech ETF Stock Performance

NYSEARCA XBI opened at $133.28 on Friday. SPDR S&P Biotech ETF has a twelve month low of $75.68 and a twelve month high of $139.19. The stock has a market capitalization of $8.65 billion, a PE ratio of 11.47 and a beta of 0.88. The stock has a 50-day simple moving average of $127.49 and a 200 day simple moving average of $121.90.

SPDR S&P Biotech ETF Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.